RxDoctor Payments DataLook up a doctor →

Matthew Lewis, MD

Family Medicine · Aurora, CONPI 1790751360

Payments from drug & device makers

$959,691in general payments, 2019–2025

Across 1,219 payments — averaging $787.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$411K
  • Novo Nordisk AS$300K
  • Regeneron$156K
  • AstraZeneca$31K
  • Astrazeneca UK Limited$24K
  • Amgen$24K
  • plus $13K from 8 others
$35,028in research payments, 2019–2025

Across 2 payments — averaging $17,514 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$35K

What the payments were for

  • Food & beverage$319100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$959,691 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$11,630
Medicare patients
70
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$17,682
EliquisApixaban14$12,787
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$12,502
Atorvastatin Calcium225$2,091
Omeprazole53$1,568
Levothyroxine Sodium166$1,213
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$902
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$872
Gabapentin22$630
Tamsulosin Hcl73$615
Albuterol Sulfate HfaAlbuterol Sulfate29$577
Bupropion Hcl SrBupropion Hcl22$522
Lisinopril90$519
Amlodipine Besylate75$465
Escitalopram Oxalate46$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$127$17,68215 claims
PfizerEliquis$27$12,78714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →